Aβ42 immunization in Alzheimer's disease generates Aβ N-terminal antibodies

Annals of Neurology

Volumn 58, Issue 3, 2005, Pages 430-435

  Lee, Michael ^a   Bard, Frederique ^a   Johnson Wood, Kelly ^a   Lee, Celeste ^a   Hu, Kang ^a   Griffith, Sue G ^a   Black, Ronald S ^b   Schenk, Dale ^a   Seubert, Peter ^a  

^a ELAN PHARMACEUTICALS   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ANTIBODY; EPITOPE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); AN-1792; PEPTIDE FRAGMENT;

ADSORPTION; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BRAIN TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MENINGOENCEPHALITIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; SENILE PLAQUE; ANTIBODY SPECIFICITY; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; EPITOPE MAPPING; IMMUNOLOGY; METABOLISM; METHODOLOGY; VALIDATION STUDY; WESTERN BLOTTING;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; EPITOPE MAPPING; EPITOPES; HUMANS; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; MENINGOENCEPHALITIS; PEPTIDE FRAGMENTS;

EID: 24644458809     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20592     Document Type: Article

References (14)

1. Schenk D, Games D, Seubert P. Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and Aβ immunization. J Mol Neurosci 2001;17:259-267.
2. Gelinas DS, DaSilva K, Fenili D, et al. Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci USA 2004;101: 14657-14662.
3. Bayer AJ, Bullock R, Jones RW, et al. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN 1792) in patients with AD. Neurology 2005;64:94-101.
4. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 2003;61:46-54.
5. Gilman S, Koller M, Black RS, et al. Clinical effects of Aβ immunization (AN 1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-1562.
6. Nicoll JAR, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med 2003;9:448-452.
7. Ferrer FI, Boada Rovira M, Sanchez Guerra ML, et al. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol 2004; 14:11-20.
8. Masliah E, Hansen L, Adame A, et al. Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology 2005;64:129-131.
9. Tribbick G. Multipin peptide libraries for antibody and receptor epitope screening and characterization. J Immunol Methods 2002;267:27-35.
10. Seubert P, Vigo-Pelfrey C, Esch F, et al. Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids. Nature 1992;359:325-327.
11. Johnson-Wood K, Lee M, Motter R, et al. Amyloid precursor protein processing and Aβ42 deposition in a transgenic model of Alzheimer's disease. Proc Natl Acad Sci USA 1997;94: 1550-1555.
12. Hock C, Konietzko U, Papassotiropoulis A, et al. Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer's disease. Nat Med 2002;8:1270-1275.
13. Bacskai BJ, Kajdasz ST, McLellan ME, et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid- in vivo by immunotherapy. J Neurosci 2002;22:7873-7878.
14. Bard F, Barbour R, Cannon C, et al. Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 2003;100:2023-2028.